Drugs that contain Linaclotide
1. Drug name - LINZESS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7371727 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 4 months from now) | |
| US7704947 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 4 months from now) | |
| US8080526 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 4 months from now) | |
| US7745409 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 4 months from now) | |
| US7304036 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Aug, 2026
(3 years from now) | |
| CN101010335A | ALLERGAN | The Method And Combination For Curing The Gastrointestinal Disease |
Sep, 2011
(11 years ago) | |
| CN102020704A | ALLERGAN | Method And Composition For The Treatment Of Gastrointestinal Disorders |
Apr, 2013
(9 years ago) | |
| CN100589839C | ALLERGAN | Polypeptide And A Pharmaceutical Composition Comprising The Polypeptide |
Jan, 2024
(1 year, 4 months from now) | |
| CN1795007A | ALLERGAN | Method And Composition For The Treatment Of Gastrointestinal Disorders |
Jan, 2024
(1 year, 4 months from now) | |
| CN101787073B | ALLERGAN | Methods And Compositions For The Treatment Of Gastrointestinal Disorders |
Jan, 2024
(1 year, 4 months from now) | |
| CN101787073A | ALLERGAN | Method And Composition For The Treatment Of Gastrointestinal Disorders |
Jan, 2024
(1 year, 4 months from now) | |
| IN200503394P1 | ALLERGAN | Methods And Compositions For The Treatment Of Gastrointestinal Disorders |
Jan, 2024
(1 year, 4 months from now) | |
| IN237521B | ALLERGAN | A Purified Peptide Which Activates The Guanylate Cyclase C Receptor For Use In Gastrointestinal Disorders |
Jan, 2024
(1 year, 4 months from now) | |
| EP1911763B1 | ALLERGAN | Compositions For The Treatment Of Gastrointestinal Disorders |
Jan, 2024
(1 year, 4 months from now) | |
| EP1911763A2 | ALLERGAN | Compositions For The Treatment Of Gastrointestinal Disorders |
Jan, 2024
(1 year, 4 months from now) | |
| EP1911763A3 | ALLERGAN | Compositions For The Treatment Of Gastrointestinal Disorders |
Jan, 2024
(1 year, 4 months from now) | |
| EP2088154B1 | ALLERGAN | Methods And Compositions For The Treatment Of Gastrointestinal Disorders |
Mar, 2025
(2 years from now) | |
| EP2088154A1 | ALLERGAN | Methods And Compositions For The Treatment Of Gastrointestinal Disorders |
Mar, 2025
(2 years from now) | |
| EP1594517A4 | ALLERGAN | Methods And Compositions For The Treatment Of Gastrointestinal Disorders |
Nov, 2027
(5 years from now) | |
| EP1594517A2 | ALLERGAN | Compositions For The Treatment Of Gastrointestinal Disorders |
Nov, 2027
(5 years from now) | |
| EP2246360A1 | ALLERGAN | Compositions For The Treatment Of Gastrointestinal Disorders |
Nov, 2027
(5 years from now) | |
| EP2246360B1 | ALLERGAN | Compositions For The Treatment Of Gastrointestinal Disorders |
Nov, 2027
(5 years from now) | |
| EP1594517B1 | ALLERGAN | Compositions For The Treatment Of Gastrointestinal Disorders |
Nov, 2027
(5 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8110553 | ALLERGAN | Methods and compositions for the treatment of gastrointestinal disorders |
Jan, 2024
(1 year, 4 months from now) | |
| US8933030 | ALLERGAN | Treatments for gastrointestinal disorders |
Feb, 2031
(8 years from now) | |
| US10702576 | ALLERGAN | Stable formulations of linaclotide |
Aug, 2031
(8 years from now) | |
| US10675325 | ALLERGAN | Stable formulations of linaclotide |
Aug, 2031
(8 years from now) | |
| US8748573 | ALLERGAN | Formulations comprising linaclotide |
Oct, 2031
(9 years from now) | |
| US8802628 | ALLERGAN | Stable solid formulation of a GC-C receptor agonist polypeptide suitable for oral administration |
Oct, 2031
(9 years from now) | |
| US9708371 | ALLERGAN | Treatments for gastrointestinal disorders |
Aug, 2033
(10 years from now) | |
Treatment: Method of treating chronic idiopathic constipation in adult patients.; method of treating irritable bowel syndrome with constipation in adults; Method of treating chronic idiopathic constipation in adult patients.; Method of treating chronic idiopathic constipation in adult patients.; method of treating irritable bowel syndrome with constipation in adult patients.; Method of treating irritable bowel syndrome with constipation in adult patients.; method of treating chronic idiopathic constipation in adult patients.
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 72MCG | CAPSULE;ORAL | Prescription |
| 145MCG | CAPSULE;ORAL | Prescription |
| 290MCG | CAPSULE;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.